£1 million project to test AI's effectiveness in Scottish NHS
A £1 million project is underway to test the safety and effectiveness of artificial intelligence in healthcare.
Funded by Innovate UK, the scheme brings together hospitals, Glasgow and Edinburgh universities, and technology companies to create a validation framework for AI tools in the Scottish NHS.
The project involves collaboration between NHS Greater Glasgow and Clyde, NHS Lothian, and AI evaluation company Aival.
Read more: 'I would not be here today': Glasgow nurse's quick thinking saves colleagues life
Dr Rishi Ramaesh, consultant radiologist and innovation fellow at NHS Lothian, said: "Artificial intelligence has tremendous potential to improve patient care, but healthcare leaders need confidence that these systems are safe and effective.
"This project will help healthcare leaders to evaluate AI, and make sure that new technologies deliver real benefits for patients."
Aival's independent evaluation platform will be used to assess AI systems for diagnosing head trauma and lung cancer, aiming to improve care for patients and support NHS staff.
The platform allows hospitals to verify AI performance using anonymised patient data and provides ongoing monitoring once the software is deployed.
The project will also test the Aival platform's ability to monitor long-term AI performance, addressing concerns about 'drift'—the decline in software accuracy over time due to changes in patient populations, disease trends, or equipment updates.
Dr Mark Hall, consultant radiologist at NHS Greater Glasgow and Clyde, said: "Post-deployment surveillance monitoring is a critical yet often overlooked aspect of patient care, especially in radiology, where early detection of disease progression can make all the difference.
"Despite its importance, there are currently no standardised guidelines.
"AI-powered monitoring software bridges this gap by providing a structured approach."
One of the challenges addressed by the project is the lengthy testing process for AI.
Currently, it can take more than nine months to evaluate a single product, and there are more than 200 AI options available for some hospital departments.
This has limited the rollout of AI solutions in clinical settings.
The project will compare six commercial AI products used in stroke and lung cancer triage, including tools developed by InferVision, Annalise-AI, and Qure.AI.
Luciana D'Adderio, Edinburgh University academic and AI evaluation and assurance expert, said: "AI technology is achieving widespread deployment across healthcare settings, yet its assurance has not received the rigorous attention it demands.
"There is an urgent need for innovative tools and technologies for AI assurance, which themselves must undergo thorough evaluation and validation.
"This critical challenge forms the cornerstone of our groundbreaking project."
Kanwal Bhati, CEO of Aival (Image: Emelie Holgersson)
Read more: New general manager expected to be 'big hit' at Glasgow care home
Kanwal Bhatia, chief executive officer and founder of Aival, said: "It's vital that we monitor and check AI that's being used in decisions on patients' health, to ensure the best outcomes for patients.
"Any healthcare workers using AI need to be sure that the product is doing what it says it does – not just now, but five years in the future.
"Putting in place effective validation systems will encourage trust and adoption of AI, and will deliver cost savings and growth in the NHS and in private healthcare.
"We work hand in hand with NHS leaders, clinical and technical teams to provide the expertise and software to ensure that their AI systems are doing what they're supposed to do."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Radiology Workforce Shortages Impacting Cancer Care
A chronic shortage of radiologists and oncologists is putting patients in the UK at risk, a new report found. The annual workforce census by the Royal College of Radiologists (RCR) warned that the safe delivery of NHS cancer care is becoming 'increasingly impossible' due to an escalating shortfall of doctors coupled with rising demand for care. In 2024, the UK had a 29% shortfall of clinical radiologists, with regional gaps ranging from 25% in Scotland to 32% in Wales. The workforce grew by 4.7% that year — less than in 2023, when it increased by 6.3%. The college forecasts the radiologist shortfall will reach 39% by 2029. Oncology Under Strain Clinical oncologists are also in short supply, with a current 15% gap expected to rise to 19% by 2029. This is despite a 5.4% increase in the workforce in 2024—the strongest growth since 2018. The RCR reported that 23% of cancer centres were experiencing recruitment freezes, making it harder to meet growing demand. Demand Continues to Outpace Capacity The shortages threaten the government's plans to cut waiting times and improve cancer outcomes. In 2024, demand for computerised tomography (CT) and magnetic resonance imaging (MRI) grew by 8%, but workforce growth did not keep pace. Every radiology leader surveyed last year reported delays to diagnostic scans caused by staff shortages. Nine in 10 radiology team leaders reported that patients were waiting longer to start treatment, while seven in 10 expressed concern that staff shortages were putting patient safety at risk – down slightly from 85% in 2023. Chronic problems such as workforce shortages, reporting backlogs, and staff vacancies remain too high, according to Dr Robin Proctor, the RCR's m edical director responsible for professional practice and clinical radiology. Consultants Leaving Earlier Staff retention is worsening, with experienced consultants leaving the NHS at younger ages. In 2024, the median age of consultant clinical radiologists leaving the NHS workforce was 50 – down from 56 in 2020. Four in five (79%) of leavers were under 60, and two in five (42%) were under 45. Clinical oncologists followed a similar trend. Their median exit age dropped to 54, from 57 in 2023 and 59 in 2022. Nearly 76% of leavers were under 60, and 26% were under 45. One consultant clinical oncologist told the college that delays in scans and treatment were resulting in missed or late cancer diagnoses. Some patients' conditions were deteriorating or reaching a stage where treatment was no longer possible. Changing Work Practices 'Working conditions and ways of working need to change if we are to address this problem and meet the growing demand for our expertise,' Proctor said. The RCR has called on the government to invest in training and recruitment. In 2024, the NHS spent an estimated £325 million on temporary radiology staff. The cost of outsourcing had doubled since before the COVID-19 pandemic and had surged by almost a quarter in the past year. The RCR estimated that increasing radiology trainee numbers by 50% could eliminate three-quarters of the current shortfall and save the NHS £460 million over the next 10 years. 'Patients are being failed by a chronic lack of radiologists and oncologists,' said RCR president Dr Katharine Halliday. 'The longer we delay action, the worse it gets,' she added.
Yahoo
an hour ago
- Yahoo
Alzheimer's blood test ‘can accurately pick up early symptoms'
A new blood test for Alzheimer's disease can accurately detect people with early symptoms, research suggests. Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. He added: 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. 'The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'
Yahoo
an hour ago
- Yahoo
‘NHS says I'm too big for surgery — now I'm spending my pension on weight-loss jabs'
With every step she takes, 72-year-old Sue Smith is in agony. The retired NHS clinician has been on the waiting list for a knee replacement for four years and walks, she says, as though her leg is broken. Despite her daily battle with pain, Ms Smith has been repeatedly denied surgery — because she is obese. But she has also been given no help by the NHS to lose weight, as waiting lists for such programmes soar. She is now forking out hundreds of pounds per month to pay for a weight-loss injection so she can have the operation she so desperately needs. Speaking to The Independent, Ms Smith — who has physically deteriorated so dramatically that she now uses a mobility scooter — said: 'I'm not lazy. I want my life back, but I'm stuck in a vicious cycle of trying to lose weight for this operation. I'm 72 years old now and am desperate for a knee replacement. 'What will they do — wait until I can't walk at all? Or I fall over and break my leg?' The Independent revealed last week that obese patients are being taken off waiting lists for life-changing hip and knee replacement surgery and being refused referrals as the NHS cuts costs. National guidelines make clear that weight should not be used to restrict patients' access to joint replacement surgery. But research has revealed more than a third of NHS areas are blocking patient access based on their body mass index (BMI). Ms Smith, who suffers from osteoarthritis, said she was told before the Covid outbreak that she needed an operation. At that time, she was fitter and slimmer and may have been eligible for the procedure, but was instead treated with steroids and physiotherapy. During the coronavirus lockdowns, the former NHS speech and language therapist struggled to maintain an active lifestyle. She was referred again for the operation in 2020 but was turned down — because her BMI was 43 — and told to lose weight. Her GP attempted to refer her for the operation three more times, but she was rejected on each occasion because of her size. Years later, with a BMI of 42, she remains above the threshold which Maidstone and Tonbridge Wells hospital set for her to be allowed an operation, she told The Independent. She said: 'The only way forward for me is to get down to this fantasy weight. I just want a knee replacement so I can exercise normally.' But Ms Smith is yet to receive any specialist weight management support from the NHS. She was finally referred for support services in January 2025 — more than four years after she was first told she could not have her operation due to weight — but was told the wait was at least 18 weeks. She is still waiting and has not heard when she will get an appointment. The Independent revealed that, in some areas, patients are waiting years for access to NHS weight loss management services. Desperate to get her operation, Ms Smith sought to get weight-loss jabs through the NHS. But, in another blow, she was told by her GP that they could not prescribe it. Under current rules, which are tightly controlling the use of such jabs, only specialist weight-loss management services can prescribe these drugs. Ms Smith has paid around £1,000 since February to have the weight loss jab Mounjaro privately, which she said has helped her to lose 18 pounds. She said: 'I get a pension from the NHS, it's about £200 a month, so really, I'm using that for this injection. I really want to have my knees done so I can move forward. I've had to buy a mobility scooter, which I don't use every day, but I have to sometimes. I don't want to be in it; I never wanted to have one. I only use it when I have to, which is once a week... It's awful, I just feel like a lesser being.' Ms Smith said that, following a recent X-ray, her GP told her knees are 'worn out.' Initially, Ms Smith said she only needed one knee replacement, however, the wait has led to her now needing surgery on both. A spokesperson for Maidstone and Tunbridge Wells NHS Trust said: 'We understand how upsetting it can be for anyone living with ongoing pain, and our teams are committed to ensuring patients receive the best possible care. While we can't comment on individual cases, referrals for surgery are assessed on a case-by-case basis, and a range of clinical factors are reviewed. 'These include, but are not limited to BMI, and enable our clinicians to ensure the surgery is safe and appropriate.'
